Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.98 EUR | -1.32% | +5.15% | +89.05% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.33M 55.12M | Sales 2025 * | 58.9M 63.25M | Capitalization | 74.8M 80.32M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M | Net income 2025 * | 3M 3.22M | EV / Sales 2024 * | 1.25 x |
Net cash position 2024 * | 10.53M 11.31M | Net cash position 2025 * | 10.63M 11.42M | EV / Sales 2025 * | 1.09 x |
P/E ratio 2024 * |
57.3
x | P/E ratio 2025 * |
20.3
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | -1.32% | ||
1 week | +5.15% | ||
Current month | +5.40% | ||
1 month | +2.51% | ||
3 months | +45.31% | ||
6 months | +122.83% | ||
Current year | +89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 8.98 | -1.32% | 3,414 |
24-06-10 | 9.1 | +2.02% | 11,259 |
24-06-07 | 8.92 | +0.45% | 4,321 |
24-06-06 | 8.88 | +2.78% | 756 |
24-06-05 | 8.64 | +1.17% | 1,747 |
Delayed Quote Xetra, June 11, 2024 at 11:36 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+89.05% | 80.24M | |
+48.53% | 780B | |
+40.67% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+16.75% | 244B | |
-1.19% | 217B | |
+10.85% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- APPH Stock